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Abstract 
Rationale: Airway colonization by Potentially Pathogenic Microorganisms (PPM) in 
bronchiectasis is associated with worse clinical outcomes. The electronic nose is a 
non-invasive technology capable of distinguishing volatile organic compounds 
(VOC) in exhaled breath. We aim to explore if an electronic nose can reliably 
discriminate airway bacterial colonization in patients with bronchiectasis. 
Methods: Seventy-three clinically stable bronchiectasis patients were included. 
PPM presence was determined using sputum culture. Exhaled breath was collected 
in Tedlar bags and VOC breath-prints were detected by the electronic nose 
Cyranose 320®. Raw data was reduced to three factors with principal component 
analysis. Univariate ANOVA followed by post-hoc least significant difference test 
was performed with these factors. Patients were then classified using linear 
canonical discriminant analysis. Cross-validation accuracy values were defined by 
the percentage of correctly classified patients. 
Results: Forty-one (56%) patients were colonized with PPM. Pseudomonas 
aeruginosa (n=27, 66%) and Haemophilus influenzae (n=7, 17%) were the most 
common PPM. VC breath-prints from colonized and non-colonized patients were 
significantly different (accuracy of 72%, AUROC 0.75, p<0.001). VOC breath-prints 
from Pseudomonas aeruginosa colonized patients were significantly different from 
those of patients colonized with other PPM (accuracy of 89%, AUROC 0.97, 
p<0.001) and non-colonized patients (accuracy 73%, AUROC 0.83, p=0.007). 
Conclusions:  An electronic nose can accurately identify VOC breath-prints of 
clinically stable bronchiectasis patients with airway bacterial colonization, especially 
in those with Pseudomonas aeruginosa. 
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Introduction 
Non-cystic fibrosis bronchiectasis (hereafter called “bronchiectasis”) is a 
chronic respiratory condition characterized by irreversible dilation of the bronchi 
and chronic airway inflammation [1]. Recent studies have observed an 
increased prevalence of bronchiectasis across Europe and the United States  
[2-4], and a high annual economic burden that increases with disease severity 
and the number of exacerbations [5]. 
Airway colonization by potentially pathogenic microorganisms (PPM) is 
an important cause of morbidity in bronchiectasis patients, and Pseudomonas 
aeruginosa is one of the pathogens most frequently isolated in those cases [6]. 
The presence of P. aeruginosa airway colonization is associated with more 
frequent exacerbations and a higher mortality rate compared to patients without 
P. aeruginosa infection [6,7]. Therefore, microbiological assessment determined 
by sputum culture analysis is one of the key factors in the characterization of 
bronchiectasis patients. However, sputum culture has limitations such as time 
delay for results and the difficulty to obtain proper sputum samples [8,9]. Thus, 
sputum analysis is not used routinely as a standard of care for the management 
of bronchiectasis patients in many hospitals [10,11]. In these cases, other 
techniques for microbiological characterization may be helpful. 
 The electronic nose (e-nose) is a non-invasive diagnostic device that 
contains an array of electronic chemical sensors capable of identifying volatile 
organic compounds (VOC) breath-prints [12,13]. The e-nose has demonstrated 
diagnostic value in identifying different airway respiratory diseases such as 
Chronic Obstructive Pulmonary Disease (COPD) [14], asthma [15] and cystic 
fibrosis (CF) [16]. Furthermore, several studies have shown that the e-nose is 
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also able to detect respiratory infections. In COPD, the e-nose has successfully 
distinguished patients with and without airway bacterial infection during clinical 
stability [17] and acute exacerbations [18]. Some studies have suggested that 
specific bacteria such as P. aeruginosa, may produce distinguishable VOC [19-
21]. The e-nose has been able to identify the presence of P. aeruginosa 
infection both in CF patients [22] and in swabs of bacteria obtained from in vitro 
cultures [23]. However, data regarding the use of the e-nose in bronchiectasis, 
and its potential role identifying P. aeruginosa is lacking. 
 We hypothesized that the e-nose could accurately discriminate VOC 
profiles from bronchiectasis patients with and without airway bacterial 
colonization, especially in those with P. aeruginosa. Therefore, the aim of this 
study was to explore if an electronic nose can reliably discriminate airway 
bacterial colonization in clinically stable patients with bronchiectasis. 
 
Methods 
Study design and Ethics 
This cross-sectional study included clinically stable bronchiectasis 
patients with and without airway bacterial colonization. The study protocol was 
approved by the institutional ethics committee (IIBSP-BRO-2013-154) and 
patients gave their informed consent. This study was registered in 
www.clinicaltrials.gov on April 2014. ClinicalTrials.gov ID: NCT02163642. 
 
Study population 
Patients were consecutively recruited from a specialist clinic at the 
Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, between June 2014 
5
 
 
and May 2016. Figure 1 shows the study approach for patient enrolment. The 
diagnosis of bronchiectasis and its etiological assessment were established 
according to national and international guidelines [1,24]. Post-infective aetiology 
was defined as patients with a history of previous severe lower respiratory tract 
infections due to bacterial and viral pneumonia, pertussis or tuberculosis [1]. 
Exclusions were: patients with age less than 18 years; unable to give informed 
consent or with other respiratory diseases such as CF, active allergic 
bronchopulmonary aspergillosis, active non-tuberculous mycobacterial infection 
or pulmonary fibrosis with traction bronchiectasis, as well as patients receiving 
immunoglobulin replacement therapy or chronic systemic corticosteroid 
treatment. Sample size was calculated as described in previous studies [17,18]. 
 
Clinical and functional assessment 
 All subjects were included during clinical stability, defined as the absence 
of an exacerbation requiring antibiotic or systemic corticosteroid treatment 
within the previous 30 days. A detailed clinical history was obtained from all 
participants, including demographic data, smoking status, relevant comorbid 
conditions, current treatment and the number of previous outpatient and 
hospitalized exacerbations. Severity of disease was assessed with the 
Bronchiectasis Severity Index (BSI) and FACED scores [25,26]. Spirometry was 
performed according to international recommendations [27], using the reference 
values for Mediterranean population [28]. 
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Bacteriology 
Spontaneous sputum samples for bacteriology were obtained from all 
participants on inclusion, and were processed as we described previously [29]. 
Quality of sputum was evaluated using the Murray-Washington criteria [30]. 
Patients were classified according to sputum bacteriology assessment into 
three groups: non-colonized, colonized by P. aeruginosa and colonized by other 
PPM (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella 
catarrhalis, Staphylococcus aureus and other Gram-negative bacilli).  
 
Exhaled breath analysis 
Breath samples were obtained from all participants to assess VOC 
profiles with the e-nose as we described previously [17,31]. In summary, 
exhaled breath samples were collected in 10 litre Tedlar bags after 3 minutes of 
tidal breathing through a Hans-Rudolph valve with an expiratory silica reservoir 
exposed to dry air and an inspiratory filter. The e-nose device (Cyranose 320®; 
Smith Detections, CA, USA), a chemical vapour analyser with 32 organic 
polymeric Nano-composite sensor arrays, was then connected to the Tedlar 
bag for 5 minutes. The exposure to exhaled breath generated a breath-print 
VOC profile for each subject. 
All participants stopped their inhaled medications and fasted for at least 
12 hours before the breath sampling. 
 
Data analysis 
Results are presented as mean and standard deviation (SD) for 
continuous parametric data, and median and interquartile range (IQR) for 
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continuous non-parametric data. Categorical data are presented as frequencies 
and percentages. Statistical analysis was performed using the SPSS 22 
software for Windows (SPSS; Illinois, USA). A p value of less than 0.05 was 
considered significant. 
Breath-print data from all participants was analysed using a pattern-
recognition application built in the MATLAB software (v.R2012a) as we 
described previously [17,31]. In short, raw data was reduced to three principal 
factors by principal component analysis (PCA). These PCA factors were used to 
perform a univariate ANOVA, followed by post-hoc least significant difference 
test. Patients were then classified into a categorical division using a linear 
canonical discriminant analysis, calculated as the one that obtained the better 
percentage of correctly classified subjects. The discriminant function was 
trained with all minus one subject samples. Then, the remaining samples were 
tested. This process known as the “leave-one-out” method was repeated for all 
subjects, thus building the percentage of correctly classified patients which 
defined cross-validation accuracy values [14,17,18,31]. A Receiver Operating 
Characteristic (ROC) was obtained using the discriminant function results. The 
area under the ROC curve was calculated with multiple logistic regression. 
 
Results 
Patient description 
Seventy-three clinically stable bronchiectasis patients were included; 47 
(64%) were female and median age was 69 years (IQR 60-76.5 years). Mean 
FEV1 was 65.9 ± 23.3% of predicted; median BSI score was 7 points (IQR 6-11 
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points) and median FACED score was 2 points (IQR 1-4 points). The most 
frequent aetiologies were post-infective (47%) and idiopathic (19%). 
Forty-one (56%) patients were classified as colonized. The most 
frequently isolated PPM were P. aeruginosa (n=27; 66%), Haemophilus 
influenzae (n=7; 17%), Escherichia coli (n=2; 5%) and Streptococcus 
pneumoniae (n=2; 5%). Other isolated PPM included Moraxella catarrhalis, 
Achromobacter xylosoxidans and Staphylococcus aureus (n=1 each, 2%).  
Baseline characteristics of colonized and non-colonized subjects are 
summarized in Table 1. Patients with airway colonization had lower lung 
function values (mean FEV1 57.6 ± 20.5 vs. 76.8 ± 22.5, p<0.001) and more 
severe bronchiectasis (BSI score median 10 vs. 6, p<0.001; FACED score 
median 3 vs. 2, p<0.001). Colonized patients were subsequently classified into 
2 subgroups according to the isolated microorganism in sputum culture; 27 
subjects (66%) were colonized with P. aeruginosa, and 14 (34%) with other 
PPM. Demographic and clinical characteristics of these subgroups are shown in 
Table 2. Patients with P. aeruginosa airway colonization were more associated 
with post-infective aetiology, had more severe bronchiectasis (BSI score 
median 11 vs. 6, p=0.01; FACED score median 4 vs. 2, p=0.001), and had a 
higher use of long-acting beta agonists (85% vs. 35%, p=0.001) and inhaled 
corticosteroids (74% vs. 35%, p=0.01) compared to those patients colonized 
with other PPM. 
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Table 1. Demographics and clinical characteristics of bronchiectasis patients with and 
without airway colonization. 
 
 Colonized (N=41) 
Non Colonized 
(N=32) p 
Age (median, IQR) 68 (60.5-77.5) 69.5 (59-75.8) 0.726 
Female gender (n,%) 25 (61%) 22 (68.8%) 0.491 
Smoking status (n,%) 
Never 
Former 
Current 
31 (75.6%) 
10 (24.4%) 
0 
24 (75%) 
7 (21.9%) 
1 (3.1%) 
0.514 
Cardiovascular disease (n,%) 9 (22%) 5 (15.6%) 0.496 
Diabetes mellitus (n,%) 4 (9.8%) 2 (6.3%) 0.588 
MRC dyspnoea score 
(median, IQR) 2 (2-3) 2 (1-2) <0.001 
Aetiology (n,%) 
Post infective 
Connective tissue disease 
Primary ciliary dyskinesia 
Immunodeficiency 
Inactive ABPA 
COPD 
Others 
Idiopathic 
 
18 (43.9%) 
7 (17.1%) 
2 (4.9%) 
2 (4.9%) 
3 (7.3%) 
1 (2.4%) 
2 (4.9%) 
6 (14.6%) 
 
16 (50%) 
2 (6.3%) 
2 (6.3%) 
1 (3.1%) 
0 
2 (6.3%) 
1 (3.1%) 
8 (25%) 
0.521 
FVC % of predicted (mean ± 
SD) 74.7 ± 18.4 87.9 ± 20.6 0.005 
FEV1 % of predicted (mean ± 
SD) 57.6 ± 20.5 76.8 ± 22.5 <0.001 
Number of exacerbations in 
the previous year (median, 
IQR) 
3 (2-4) 2 (1-3) 0.392 
Bronchiectasis severity 
index score (median, IQR) 10 (6-13) 6 (4-8) <0.001 
FACED score (median, IQR) 3 (2-4) 2 (1-3) <0.001 
LABA use (n,%) 28 (68.3%) 18 (56.3%) 0.290 
LAMA use (n,%) 19 (46.3%) 8 (25%) 0.061 
ICS use (n,%) 25 (61%) 16 (50%) 0.348 
Chronic macrolides (n,%) 10 (24.4%) 6 (18.8%) 0.563 
 
All data is presented in median (quartiles 1-3) unless otherwise indicated. 
MRC: Medical Research Council; ABPA: Allergic bronchopulmonary aspergillosis; COPD: 
Chronic obstructive pulmonary disease; FVC: Forced vital capacity; FEV1: Forced expiratory 
volume in 1 second; SABA: Short-acting beta agonists; LABA: Long-acting beta agonists; 
LAMA: Long-acting muscarinic receptor antagonists; ICS: Inhaled corticosteroids. 
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Table 2. Demographics and clinical characteristics of bronchiectasis patients with 
airway colonization by Pseudomonas aeruginosa and other potentially pathogenic 
microorganisms. 
 
 Colonized with P. aeruginosa (N=27) 
Colonized with 
other PPM (N=14) p 
Age (median, IQR) 68 (63-77) 67 (58-78) 0.591 
Female gender (n,%) 18 (66.7%) 7 (50%) 0.300 
Smoking status (n,%) 
Never 
Former 
Current 
 
19 (70.4%) 
8 (29.6%) 
0 
 
12 (85.7%) 
2 (14.3%) 
0 
 
 
0.278 
MRC dyspnoea score 
(median, IQR) 3 (2-3) 2 (2-3) 0.166 
Aetiology (n,%) 
Post infective 
Connective tissue disease 
Primary ciliary dyskinesia 
Immunodeficiency 
Inactive ABPA 
COPD 
Others 
Idiopathic 
 
16 (59.3%) 
2 (7.4%) 
0 
0 
2 (7.4%) 
1 (3.7%) 
1 (3.7%) 
5 (18.5%) 
 
2 (14.3%) 
5 (35.7%) 
2 (14.3%) 
2 (14.3%) 
1 (7.1%) 
0 
1 (7.1%) 
1 (7.1%) 
 
 
 
0.013 
FVC % of predicted (mean 
± SD) 72.3 ± 19.1 79.4 ± 16.6 0.248 
FEV1 % of predicted 
(mean ± SD) 54.9 ± 22.2 62.7 ± 16.2 0.251 
Number of exacerbations 
in the previous year 
(median, IQR) 
3 (2-4) 2.5 (1-3.3) 0.370 
Bronchiectasis severity 
index score (median, IQR) 11 (9-14) 6 (5.8-12.5) 0.016 
FACED score (median, 
IQR) 4 (2-5) 2 (1-3) 0.001 
LABA use (n,%) 23 (85.2%) 5 (35.7%) 0.001 
LAMA use (n,%) 14 (51.9%) 5 (35.7%) 0.326 
ICS use (n,%) 20 (74.1%) 5 (35.7%) 0.017 
Chronic macrolides (n,%) 7 (25.9%) 3 (21.4%) 0.750 
 
All data is presented in median (quartiles 1-3) unless otherwise indicated. 
PPM: Potentially pathogenic microorganisms; MRC: Medical Research Council; ABPA: Allergic 
bronchopulmonary aspergillosis; COPD: Chronic obstructive pulmonary disease; FVC: Forced 
vital capacity; FEV1: Forced expiratory volume in 1 second; SABA: Short-acting beta agonists; 
LABA: Long-acting beta agonists; LAMA: Long-acting muscarinic receptor antagonists; ICS: 
Inhaled corticosteroids. 
 
Breath-print analysis 
Bronchiectasis patients with and without airway bacterial colonization had 
significantly different breath profiles (Figure 2). Cross-validation accuracy was 
72.1%, and Area under ROC curve (AUROC) was 0.75 (p=0.01) (Table 3).  
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Subjects with airway bacterial colonization were then analysed. VOC 
breath-print profiles from subjects colonized by P. aeruginosa and by other PPM 
were markedly different (Figure 3), with a cross-validation accuracy of 89.2% 
and AUROC of 0.96 (p<0.001) (Table 3). 
In addition, patients with P. aeruginosa airway colonization were 
compared with non-colonized subjects. This analysis also showed significant 
differences in breath-print profiles (Figure 4), with a cross-validation accuracy 
of 72.7% and AUROC of 0.82 (p=0.007) (Table 3).  
 
Table 3. Receiver operating characteristics analyses of breath-prints between 
bronchiectasis patients with Pseudomonas aeruginosa colonization, other PPM 
colonization and non-colonized. 
 
 
Colonized vs. 
non-colonized 
bronchiectasis 
patients 
P. aeruginosa 
colonized vs. 
other PPM 
colonized 
bronchiectasis 
patients 
P. aeruginosa 
colonized vs. 
non-colonized 
bronchiectasis 
patients 
Cross-validation accuracy 72.1% 89.2% 72.7% 
Sensitivity 0.84 0.92 0.83 
Specificity 0.58 0.85 0.65 
AUROC 0.754 0.968 0.829 
Positive predictive value 0.70 0.92 0.65 
Negative predictive value 0.75 0.85 0.83 
p value 0.01 <0.001  0.007 
 
PPM: Potentially pathogenic microorganisms; AUROC: Area under receiver operating 
characteristic. 
 
 
Discussion 
 This study showed that an electronic nose is a non-invasive technology 
capable of identifying VOC breath-prints from bronchiectasis patients with and 
without airway bacterial colonization. Moreover, it can accurately distinguish 
breath-prints of bronchiectasis subjects with P. aeruginosa airway colonization 
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from those colonized with other PPM and non-colonized. These findings 
suggest that the e-nose could be a useful tool to identify airway bacterial 
colonization in clinically stable bronchiectasis patients. 
Airway bacterial colonization by PPM is one of the most frequent and 
important causes of morbidity in bronchiectasis patients. Different studies have 
observed that patients with airway bacterial colonization, either by P. 
aeruginosa or other PPM, have worse clinical outcomes and more severity of 
disease than non-colonized patients [9,25]. Our study showed a 56% 
prevalence of colonized patients during clinical stability, and overall these 
patients also had a history of more frequent exacerbations, lower FEV1 values 
and more severe disease. Identifying airway bacterial colonization is important 
because of its prognostic significance and also because most therapies for 
bronchiectasis such as inhaled antibiotics, target airway infection. We 
previously demonstrated an accurate discrimination of COPD patients with and 
without airway bacterial colonization using the e-nose (sensitivity of 82%; 
specificity of 96%) [17]. In this study, bronchiectasis patients with airway 
colonization also had different VOC breath-prints compared to non-colonized 
ones using the same e-nose technology (sensitivity of 84%; specificity of 58%). 
Our study showed a 56% prevalence of PPM airway colonization. This 
prevalence varies widely between cohorts and countries. Martinez-Garcia et al. 
observed a PPM airway colonization prevalence of approximately 32% for P. 
aeruginosa, 15% for Haemophilus influenzae and 5% for other Gram-negative 
bacteria [26]. In a different cohort, King and collaborators found a higher 
colonization rate but predominantly by Haemophilus influenzae (47%), P. 
aeruginosa (12%), Moraxella catarrhalis (8%) and Streptococcus pneumoniae 
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(7%) [32]. Meanwhile, another study from Chalmers et al. showed a chronic 
colonization prevalence of approximately 72%, with predominance of 
Haemophilus influenzae (40%), P. aeruginosa (16%) and Moraxella catarrhalis 
(14%) [25]. This shows there is a wide range of PPM colonization rates among 
bronchiectasis patients. 
P. aeruginosa is a pathogen frequently associated with airway 
colonization in bronchiectasis [6]. It has been demonstrated that bronchiectasis 
patients colonized by P. aeruginosa have more frequent exacerbations, a 
steeper decline in FEV1 and a higher mortality rate than other patients 
[6,7,9,25,26]. In addition, patients with airway P. aeruginosa colonization have 
shown higher levels of sputum mucins and airway cytokines, chemokines and 
neutrophil elastase when compared to other bronchiectasis subjects [29,33]. 
Neutrophil elastase is also related to worse clinical outcomes and disease 
severity [34]. In our study, P. aeruginosa was the most frequently isolated PPM 
in 66% of the colonized patients, and as described in previous studies, these 
subjects had worse lung function values and higher severity scores. Therefore, 
it is important not only to identify airway bacterial colonization but also to 
discriminate the presence of specific PPM such as P. aeruginosa. 
Several studies have used the e-nose technology to discriminate 
between airway colonization by different PPM, based on the fact that VOC may 
be produced as a part of bacterial metabolism [35,36]. Lai et al. successfully 
used the e-nose on swabs from in vitro samples to discriminate VOC patterns of 
common respiratory bacterial pathogens such as H. influenzae, S. pneumoniae, 
S. aureus and P. aeruginosa from control samples [23]. Using the same e-nose 
as in our study, Shafiek et al [18] demonstrated that COPD patients expressed 
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different VOC profiles during infectious exacerbations depending on the 
causative bacteria, especially when comparing P. aeruginosa versus H. 
influenzae, although only 8 patients were included in this comparison. In our 
study, using a higher sample size, the e-nose showed a high accuracy to 
discriminate VOC breath-prints between airway colonization by different 
microorganisms, especially when comparing P. aeruginosa with other PPM 
(sensitivity of 92%, specificity of 85%). This high accuracy value may be related 
to the presence of a specific VOC pattern for different PPM [23,37]. In this 
order, Goeminne et al. used gas chromatography-mass spectrometry on sputa 
from bronchiectasis patients to assess P. aeruginosa airway colonization status, 
and observed that not a single but a pattern of VOC are related to the presence 
of this microorganism [37]. To our knowledge, this is the first study in stable 
bronchiectasis patients to explore the utility of the e-nose technology not only 
for discriminating colonized from non-colonized subjects, but also for identifying 
the presence of P. aeruginosa airway colonization. 
A key limitation of this study is the relatively small sample size obtained 
from a single centre and the lack of external validation; however we have 
previously validated the utility of the e-nose in a smaller COPD cohort [17] and 
several studies using the same device have lower sample sizes [15,16,31]. In 
addition, the characteristics of patients in our centre are very similar to those 
reported from across Europe in terms of demographics, aetiology and 
bacteriology. This greatly strengthens the generalisability of this study [38,39]. 
Another limitation is the use of sputum analysis for bacteriology assessment, 
due to the difficulty of some patients to obtain a good sputum sample and the 
possibility of contamination with bacteria from the upper respiratory tract. 
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Nevertheless, the quality of all samples included was evaluated using the 
Murray-Washington criteria as mentioned above. We consciously decided not to 
perform molecular diagnostics such as PCR or microbiome characterization 
since their clinical and prognostic relevance need further evaluation, and 
sputum sampling is still the standard of care for microbiological assessment in 
bronchiectasis patients and has a good correlation with results from 
bronchoscopic procedures in these subjects [40]. In this study it is not possible 
to affirm whether we are identifying P. aeruginosa airway presence, disease 
severity or medication use. However, bacterial colonization is associated with 
disease severity and stratifying colonized patients by their severity of disease 
was not possible due to the low number of non-severe colonized subjects. Also, 
breath samples were obtained after 12 hours of stopping any inhaled 
medication in order to avoid this potential confounding factor. Finally, we did not 
use gas chromatography or mass spectrometry to study the molecular 
correspondence of the different VOC patterns. A study aiming to identify the 
different compounds that characterize each group would be of great interest. 
In conclusion, the electronic nose is a non-invasive technology that 
shows promising results in the identification of VOC breath-prints related to 
airway bacterial colonization in bronchiectasis patients during clinical stability, 
especially in those colonized by P. aeruginosa. Therefore, it may become a 
useful tool alongside sputum microbiology to improve the proper management 
of bronchiectasis patients. 
 
 
 
16
 
 
Acknowledgments 
 
Authorship: Conception and design: OS, GSC, JG. Data acquisition and 
interpretation: OS, GSC, JG, JLM, ART, AF, LP, FSR, DC, VP, JDC. Data 
analysis: OS, GSC, JG, JLM, JDC. Preparation of the manuscript: OS, GSC, 
JG, JLM, JDC. All authors have critically revised and given their final approval 
of the manuscript. 
 
Support: This project was supported by: Sociedad Española de Neumología y 
Cirugía Torácica (SEPAR), Societat Catalana de Pneumologia (SOCAP) and 
Fundación AstraZeneca (Programa de Fomento de los jóvenes científicos 
españoles). 
 
 
 
 
 
 
 
 
 
 
 
 
 
17
 
 
References 
[1] M.C. Pasteur, D. Bilton,  a. T. Hill, British Thoracic Society guideline for 
non-CF bronchiectasis, Thorax. 65 (2010) i1–i58. 
doi:10.1136/thx.2010.136119. 
[2] F.C. Ringshausen, A. De Roux, R. Diel, D. Hohmann, T. Welte, J. 
Rademacher, Bronchiectasis in Germany: A population-based estimation 
of disease prevalence, Eur. Respir. J. 46 (2015) 1805–1807. 
doi:10.1183/13993003.00954-2015. 
[3] J.K. Quint, E.R.C. Millett, M. Joshi, V. Navaratnam, S.L. Thomas, J.R. 
Hurst, L. Smeeth, J.S. Brown, Changes in the incidence, prevalence and 
mortality of bronchiectasis in the UK from 2004 to 2013: a population-
based cohort study, Eur. Respir. J. 47 (2016) 186–193. 
doi:10.1183/13993003.01033-2015. 
[4] A.E. Seitz, K.N. Olivier, C. a. Steiner, R.M. De Oca, S.M. Holland, D.R. 
Prevots, Trends and burden of bronchiectasis-associated hospitalizations 
in the United States, 1993-2006, Chest. 138 (2010) 944–949. 
doi:10.1378/chest.10-0099. 
[5] D. De La Rosa, M.-A. Martínez-Garcia, C. Olveira, R. Girón, L. Máiz, C. 
Prados, Annual direct medical costs of bronchiectasis treatment, Chron. 
Respir. Dis. 13 (2016) 361–371. doi:10.1177/1479972316643698. 
[6] S. Finch, M.J. McDonnell, H. Abo-Leyah, S. Aliberti, J.D. Chalmers, A 
Comprehensive Analysis of the Impact of Pseudomonas aeruginosa 
Colonisation on Prognosis in Adult Bronchiectasis., Ann. Am. Thorac. 
Soc. 12 (2015) 1602–11. doi:10.1513/AnnalsATS.201506-333OC. 
[7] M.A. Martínez-García, J.-J. Soler-Cataluña, M. Perpiñá-Tordera, P. 
18
 
 
Román-Sánchez, J. Soriano, Factors associated with lung function 
decline in adult patients with stable non-cystic fibrosis bronchiectasis., 
Chest. 132 (2007) 1565–1572. doi:10.1378/chest.07-0490. 
[8] J.R. Lentino, D.A. Lucks, Nonvalue of sputum culture in the management 
of lower respiratory tract infections, J. Clin. Microbiol. 25 (1987) 758–762. 
[9] S. Aliberti, S. Lonni, S. Dore, M.J. McDonnell, P.C. Goeminne, K. 
Dimakou, T.C. Fardon, R. Rutherford, A. Pesci, M.I. Restrepo, G. Sotgiu, 
J.D. Chalmers, Clinical phenotypes in adult patients with bronchiectasis, 
Eur. Respir. J. 47 (2016) 1113–1122. doi:10.1183/13993003.01899-2015. 
[10] A.T. Hill, C. Routh, S. Welham, National BTS bronchiectasis audit 2012: 
is the quality standard being adhered to in adult secondary care?, Thorax. 
69 (2014) 292–294. doi:10.1136/thoraxjnl-2013-203739. 
[11] S. Aliberti, A.T. Hill, M. Mantero, S. Battaglia, S. Centanni, S. Lo Cicero, 
D. Lacedonia, M. Saetta, J.D. Chalmers, F. Blasi, C. Morrone, M. Basile, 
G.F.S. Papa, C. Conti, M.P.F. Barbaro, K. Lokar-Oliani, P. Schino, M. 
Vitacca, F. Menzella, A. Sanduzzi, P. Usai, M. Carone, D.R. Bonardi, N. 
Crimi, G. Schiraldi, A. Corsico, M. Malerba, F. Becciu, P. Santus, G. 
Girbino, A. Foresi, V. Comellini, C. Stochino, P. Ceriana, V. Conti, F. 
Braido, V. Mastrosimone, N. Ciancio, M. Berlendis, F. De Blasio, S.C. 
Conte, A. Vatrella, Quality standards for the management of 
bronchiectasis in Italy: A national audit, Eur. Respir. J. 48 (2016) 244–
248. doi:10.1183/13993003.00232-2016. 
[12] A.P.F. Turner, N. Magan, Innovation: Electronic noses and disease 
diagnostics, Nat. Rev. Microbiol. 2 (2004) 161–166. 
doi:10.1038/nrmicro823. 
19
 
 
[13] S. Scarlata, G. Pennazza, M. Santonico, C. Pedone, R. Antonelli Incalzi, 
Exhaled breath analysis by electronic nose in respiratory diseases, Expert 
Rev. Mol. Diagn. 15 (2015) 933–956. 
doi:10.1586/14737159.2015.1043895. 
[14] N. Fens, A.H. Zwinderman, M.P. Van Der Schee, S.B. De Nijs, E. Dijkers, 
A.C. Roldaan, D. Cheung, E.H. Bel, P.J. Sterk, Exhaled breath profiling 
enables discrimination of chronic obstructive pulmonary disease and 
asthma, Am. J. Respir. Crit. Care Med. 180 (2009) 1076–1082. 
doi:10.1164/rccm.200906-0939OC. 
[15] S. Dragonieri, R. Schot, B.J.A. Mertens, S. Le Cessie, S.A. Gauw, A. 
Spanevello, O. Resta, N.P. Willard, T.J. Vink, K.F. Rabe, E.H. Bel, P.J. 
Sterk, An electronic nose in the discrimination of patients with asthma and 
controls, J. Allergy Clin. Immunol. 120 (2007) 856–862. 
doi:10.1016/j.jaci.2007.05.043. 
[16] T. Paff, M.P. van der Schee, J.M.A. Daniels, G. Pals, P.E. Postmus, P.J. 
Sterk, E.G. Haarman, Exhaled molecular profiles in the assessment of 
cystic fibrosis and primary ciliary dyskinesia, J. Cyst. Fibros. 12 (2013) 
454–460. doi:10.1016/j.jcf.2012.12.010. 
[17] O. Sibila, L. Garcia-Bellmunt, J. Giner, J.L. Merino, G. Suarez-Cuartin, A. 
Torrego, I. Solanes, D. Castillo, J.L. Valera, B.G. Cosio, V. Plaza, A. 
Agusti, Identification of airway bacterial colonization by an electronic nose 
in Chronic Obstructive Pulmonary Disease., Respir. Med. 108 (2014) 
1608–14. doi:10.1016/j.rmed.2014.09.008. 
[18] H. Shafiek, F. Fiorentino, J.L. Merino, C. López, A. Oliver, J. Segura, I. de 
Paul, O. Sibila, A. Agustí, B.G. Cosío, Using the Electronic Nose to 
20
 
 
Identify Airway Infection during COPD Exacerbations., PLoS One. 10 
(2015) e0135199. doi:10.1371/journal.pone.0135199. 
[19] A.J. Scott-Thomas, M. Syhre, P.K. Pattemore, M. Epton, R. Laing, J. 
Pearson, S.T. Chambers, 2-Aminoacetophenone as a potential breath 
biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung., BMC 
Pulm. Med. 10 (2010) 56. doi:10.1186/1471-2466-10-56. 
[20] F.J. Gilchrist, R.J. Bright-Thomas, A.M. Jones, D. Smith, P. Španěl, A.K. 
Webb, W. Lenney, Hydrogen cyanide concentrations in the breath of adult 
cystic fibrosis patients with and without Pseudomonas aeruginosa 
infection, J. Breath Res. 7 (2013) 26010. doi:10.1088/1752-
7155/7/2/026010. 
[21] F.J. Gilchrist, J. Belcher, A.M. Jones, D. Smith, A.R. Smyth, K.W. 
Southern, P. Spanel, A.K. Webb, W. Lenney, Exhaled breath hydrogen 
cyanide as a marker of early Pseudomonas aeruginosa infection in 
children with cystic fibrosis, ERJ Open Res. 1 (2015) 44-2015-44–2015. 
doi:10.1183/23120541.00044-2015. 
[22] O. Joensen, T. Paff, E.G. Haarman, I.M. Skovgaard, P.Ø. Jensen, T. 
Bjarnsholt, K.G. Nielsen, Exhaled Breath Analysis Using Electronic Nose 
in Cystic Fibrosis and Primary Ciliary Dyskinesia Patients with Chronic 
Pulmonary Infections, PLoS One. 9 (2014) e115584. 
doi:10.1371/journal.pone.0115584. 
[23] S.Y. Lai, O.F. Deffenderfer, W. Hanson, M.P. Phillips, E.R. Thaler, 
Identification of upper respiratory bacterial pathogens with the electronic 
nose., Laryngoscope. 112 (2002) 975–979. doi:10.1097/00005537-
200206000-00007. 
21
 
 
[24] M. Vendrell, J. de Gracia, C. Olveira, M. Ángel Martínez, R. Girón, L. 
Máiz, R. Cantón, R. Coll, A. Escribano, A. Solé, Diagnóstico y tratamiento 
de las bronquiectasias, Arch. Bronconeumol. 44 (2008) 629–640. 
doi:10.1157/13128330. 
[25] J.D. Chalmers, P. Goeminne, S. Aliberti, M.J. McDonnell, S. Lonni, J. 
Davidson, L. Poppelwell, W. Salih, A. Pesci, L.J. Dupont, T.C. Fardon, A. 
De Soyza, A.T. Hill, The bronchiectasis severity index an international 
derivation and validation study, Am. J. Respir. Crit. Care Med. 189 (2014) 
576–585. doi:10.1164/rccm.201309-1575OC. 
[26] M. a. Martínez-García, J. De Gracia, M.V. Relat, R.M. Girón, L.M. Carro, 
D. De La Rosa Carrillo, C. Olveira, Multidimensional approach to non-
cystic fibrosis bronchiectasis: The FACED score, Eur. Respir. J. 43 (2014) 
1357–1367. doi:10.1183/09031936.00026313. 
[27] G. Laszlo, Standardisation of lung function testing: helpful guidance from 
the ATS/ERS Task Force, Thorax. 61 (2006) 744–746. 
doi:10.1136/thx.2006.061648. 
[28] J. Roca, J. Sanchis, A. Agusti-Vidal, F. Segarra, D. Navajas, R. 
Rodriguez-Roisin, P. Casan, S. Sans, Spirometric reference values from 
a Mediterranean population, Bull Eur Physiopathol Respir. 22 (1986) 217–
224. 
[29] O. Sibila, G. Suarez-Cuartin, A. Rodrigo-Troyano, T.C. Fardon, S. Finch, 
E.F. Mateus, L. Garcia-Bellmunt, D. Castillo, S. Vidal, F. Sanchez-Reus, 
M.I. Restrepo, J.D. Chalmers, Secreted mucins and airway bacterial 
colonization in non-CF bronchiectasis., Respirology. 20 (2015) 1082–8. 
doi:10.1111/resp.12595. 
22
 
 
[30] P.R. Murray, J.A. Washington, Microscopic and baceriologic analysis of 
expectorated sputum., Mayo Clin. Proc. 50 (1975) 339–344. 
[31] V. Plaza, A. Crespo, J. Giner, J.L. Merino, D. Ramos-Barbón, E.F. 
Mateus, A. Torrego, B.G. Cosio, A. Agustí, O. Sibila, Inflammatory 
asthma phenotype discrimination using an electronic nose breath 
analyzer, J. Investig. Allergol. Clin. Immunol. 25 (2015) 431–437. 
[32] P.T. King, S.R. Holdsworth, N.J. Freezer, E. Villanueva, P.W. Holmes, 
Microbiologic follow-up study in adult bronchiectasis, Respir. Med. 101 
(2007) 1633–1638. doi:10.1016/j.rmed.2007.03.009. 
[33] J.D. Chalmers, M.P. Smith, B.J. McHugh, C. Doherty, J.R. Govan, A.T. 
Hill, Short- and long-term antibiotic treatment reduces airway and 
systemic inflammation in non-cystic fibrosis bronchiectasis, Am. J. Respir. 
Crit. Care Med. 186 (2012) 657–665. doi:10.1164/rccm.201203-0487OC. 
[34] J.D. Chalmers, K.L. Moffitt, G. Suarez-Cuartin, O. Sibila, S. Finch, E. 
Furrie, A. Dicker, K. Wrobel, J.S. Elborn, B. Walker, S.L. Martin, S.E. 
Marshall, J.T.-J. Huang, T.C. Fardon, Neutrophil Elastase Activity is 
Associated with Exacerbations and Lung Function Decline in 
Bronchiectasis., Am. J. Respir. Crit. Care Med. (2016). 
doi:10.1164/rccm.201605-1027OC. 
[35] S. Schulz, J.S. Dickschat, Bacterial volatiles: the smell of small 
organisms., Nat. Prod. Rep. 24 (2007) 814–842. doi:10.1039/b507392h. 
[36] R.M.S. Thorn, J. Greenman, Microbial volatile compounds in health and 
disease conditions, J. Breath Res. 6 (2012) 24001. doi:10.1088/1752-
7155/6/2/024001. 
[37] P.C. Goeminne, T. Vandendriessche, J. Van Eldere, B.M. Nicolai, M.L. 
23
 
 
Hertog, L.J. Dupont, Detection of Pseudomonas aeruginosa in sputum 
headspace through volatile organic compound analysis, Respir. Res. 13 
(2012) 87. doi:10.1186/1465-9921-13-87. 
[38] S. Lonni, J.D. Chalmers, P.C. Goeminne, M.J. McDonnell, K. Dimakou, A. 
De Soyza, E. Polverino, C. Van de Kerkhove, R. Rutherford, J. Davison, 
E. Rosales, A. Pesci, M.I. Restrepo, S. Aliberti, Etiology of Non-Cystic 
Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity., 
Ann. Am. Thorac. Soc. 12 (2015) 1764–70. 
doi:10.1513/AnnalsATS.201507-472OC. 
[39] M.J. McDonnell, S. Aliberti, P.C. Goeminne, M.I. Restrepo, S. Finch, A. 
Pesci, L.J. Dupont, T.C. Fardon, R. Wilson, M.R. Loebinger, D. Skrbic, D. 
Obradovic, A. De Soyza, C. Ward, J.G. Laffey, R.M. Rutherford, J.D. 
Chalmers, Comorbidities and the risk of mortality in patients with 
bronchiectasis: an international multicentre cohort study, Lancet Respir. 
Med. 4 (2016) 969–979. doi:10.1016/S2213-2600(16)30320-4. 
[40] J. Angrill, C. Agustí, R. de Celis, A. Rañó, J. Gonzalez, T. Solé, A. 
 Xaubet, R. Rodriguez-Roisin, A. Torres, Bacterial colonisation in patients 
 with bronchiectasis: microbiological pattern and risk factors., Thorax. 57 
 (2002) 15–9. 
 
 
 
 
 
 
24
 
 
Figure Legends 
 
Figure 1. Flow diagram of study approach for patient enrolment  
 
Figure 2. Electronic nose discrimination of colonized vs. non-colonized 
bronchiectasis patients. 
 
 
A: Two-dimensional principal component (PC) analyses plot showing the 
breath-print discrimination.  
B: Area Under Roc Curve (AUROC) of 0.75 
 
C: Colonized; NC: Non-colonized. 
 
 
Figure 3. Electronic nose discrimination of airway colonization with 
Pseudomonas aeruginosa vs. airway colonization with other potentially 
pathogenic bacteria in bronchiectasis patients. 
 
 
A: Two-dimensional principal component (PC) analyses plot showing the 
breath-print discrimination.  
B: Area Under Roc Curve (AUROC) of 0.96 
 
C-PA: Colonization with Pseudomonas aeruginosa; C-O: Colonization with 
other potentially pathogenic microorganisms. 
 
 
Figure 4. Electronic nose discrimination of bronchiectasis patients with 
Pseudomonas aeruginosa airway colonization vs. non-colonized subjects. 
 
 
A: Two-dimensional principal component (PC) analyses plot showing the 
breath-print discrimination.  
B: Area Under Roc Curve (AUROC) of 0.82. 
 
C-PA: Colonization with Pseudomonas aeruginosa; NC: Non-colonized. 
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